Roivant Sciences (ROIV) Long-Term Investments (2021 - 2024)
Roivant Sciences (ROIV) posted Long-Term Investments of $163.0 million for Q4 2024, up 0.75% on a QoQ basis from $161.8 million in Q3 2024, and up 19.92% year-over-year from $135.9 million in Q1 2024.
Roivant Sciences (ROIV) Long-Term Investments (2021 - 2024) Analysis & Trends
Roivant Sciences' Long-Term Investments history runs 4 years deep, the most recent figure standing at $163.0 million for Q4 2024.
- Quarterly Long-Term Investments rose 19.92% year-over-year to $163.0 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $163.0 million (up 19.92% YoY) and the FY2024 annual result came in at $163.0 million, up 19.92% from the prior year.
- Long-Term Investments was $163.0 million for Q4 2024 at Roivant Sciences, up from $161.8 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $220.0 million in Q3 2021 and bottomed at $100.6 million in Q2 2021.
- A 4-year average of $165.8 million and a median of $163.0 million in 2024 frame the typical range for Long-Term Investments.
- Peak annual rise in Long-Term Investments reached 19.92% in 2024, while the deepest fall reached 17.39% in 2024.
- Roivant Sciences' Long-Term Investments stood at $215.7 million in 2021, then fell by 10.07% to $194.0 million in 2022, then dropped by 29.92% to $135.9 million in 2023, then advanced by 19.92% to $163.0 million in 2024.
- Business Quant data shows ROIV's Long-Term Investments at $163.0 million in Q4 2024, $161.8 million in Q3 2024, and $142.9 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 505,194.89 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 9.79 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Roivant Sciences | 24.35 Bn | 25.12 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 163.01 Mn |
| Sep 30, 2024 | 161.79 Mn |
| Jun 30, 2024 | 142.94 Mn |
| Mar 31, 2024 | 147.53 Mn |
| Dec 31, 2023 | 135.93 Mn |
| Sep 30, 2023 | 164.33 Mn |
| Mar 31, 2023 | 178.58 Mn |
| Mar 31, 2022 | 193.96 Mn |
| Dec 31, 2021 | 215.68 Mn |
| Sep 30, 2021 | 219.98 Mn |
| Jun 30, 2021 | 100.56 Mn |